Archive for March, 2012

Biosimilars: Current Situation & Future Prospects, Worldwide

BiotechBlog partner DrugPatentWatch is proud to announce the availability of a new report in the reports store. Biosimilars: Current Situation & Future Prospects, Worldwide The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator […]


North Carolina Joins Mid-Atlantic Bio

Exciting Mid-atlantic news — North Carolina has joined Mid Atlantic Bio. I’ve always enjoyed attending the Mid-Atlantic BIO conference, at it covers a good diversity of biotechnology companies in Maryland and Virginia. There has also been representation from North Carolina in the past, so it’s nice to see that NC has formally joined the group. […]


Free Trial Subscriptions from Journal of Commercial Biotechnology

The Journal of Commercial Biotechnology is offering free trial subscriptions for a limited time. Use the free trial subscription form to sign up for a free trial. The Journal of Commercial Biotechnology, in print since 1994, is the definitive international quarterly publication for bioscience business professionals. The Journal is designed specifically for those professionals who […]


Drug Patent Expirations in March 2012

Drug Patent Expirations in March 2012 *Drugs may be covered by multiple patents Tradename Applicant Generic Name Patent Number Patent Expiration GEODON Pfizer ziprasidone mesylate 4,831,031 Mar 2, 2012 GEODON Pfizer Inc ziprasidone hydrochloride 4,831,031 Mar 2, 2012 GEODON Pfizer ziprasidone hydrochloride 4,831,031 Mar 2, 2012 ZOFRAN Glaxosmithkline ondansetron hydrochloride 5,344,658*PED Mar 6, 2012 GENESA […]